{
  "image_filename": "figure_p1_det_0_017.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/figure_p1_det_0_017.png",
  "image_type": "Figure",
  "page_number": 1,
  "block_id": "det_0_017",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "Title page of an original research article titled \"Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age\" listing authors and the start of the abstract section. does not support the claim because the image contains only the article title and author list without any data or statements regarding immune response breadth or cross-protection in mismatch seasons Note: Limited to the title page; no study results or conclusions are visible",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Title page of an original research article titled \"Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age\" listing authors and the start of the abstract section.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the image contains only the article title and author list without any data or statements regarding immune response breadth or cross-protection in mismatch seasons",
    "confidence_notes": "Limited to the title page; no study results or conclusions are visible"
  }
}